HUDDINGE, Sweden, Feb. 15, 2002 (PRIMEZONE) -- Medivir:
-- MIV-606 against shingles: Outlicensing activities are in an
intensive phase.
-- In December, Medivir and Peptimmune announced a research
breakthrough in the treatment of RA (rheumatoid arthritis).
-- In the fourth quarter 2001, Medivir selected a CD (candidate
drug) in its HIV polymerase research program.
-- MIV-310 against multi-resistant HIV-phase IIa trial began in
October.
-- MIV-210 against hepatitis B-phase I trial demonstrated good
oral bioavailability.
-- In August, Medivir signed a preclinical research agreement on
hepatitis C with Chiron.
-- Also in August, Medivir entered a new antibiotics research
collaboration with scientists at Bart's and the London School of
Medicine, Queen Mary College, the University of London.
-- ME-609 against oral herpes-definitive phase II trial results
demonstrated good efficacy; ME-609 is also the first
pharmaceutical to prevent the incidence of cold sores with early
treatment. Strategy ahead of forthcoming phase III trials
finalized; outlicensing efforts recently initiated.
-- Profit after financial items was SEK -139.4 m (-85.4 m); net
sales grew to SEK 125.9 m (110.4 m).
-- CCS increased net sales to SEK 126.4 m (77.7 m), with operating
profit of SEK 16.4 m (15.0 m).
Forthcoming financial information in 2002
-- The Annual General Meeting will be held on 9 April 2002
-- The First-quarter Interim Report will be published on
26 April 2002
-- The Second-quarter Interim Report will be published on
8 July 2002
-- The Third-quarter Interim Report will be published on
31 October 2002
Teleconference
Medivir will host a teleconference at 15.00 SE time. Jonas Frick, CEO and President; Bertil Samuelsson, Head of Research; Johan Harmenberg, Head of Pharmaceutical Development and Rein Piir, CFO and IR will guide you through the financial statement for 2001 and a Q&A session will be held.
For participance please dial +44 (0)20 8781 0562, code medivir. The teleconference will be recorded and saved for 7 days. To reach the recorded version please dial +44 (0)20 8288 4459 and use code 670 812 from 17.00 SE time.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2002/02/15/20020215BIT00750/bit0001.doc Full Year-End Report www.waymaker.net/bitonline/2002/02/15/20020215BIT00750/bit0001.pdf Full Year-End Report